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ABSTRACT
The high cost per patient of hematopoietic cell transplantation (HCT) causes this therapy to be the focus of
much controversy, given the competing societal demands to provide all possible therapy to preserve life while
simultaneously limiting global health care expenditures. Treatment and eligibility decisions for HCT often are
heavily scrutinized by both governmental and private payers and not simply determined by physicians, facility
providers, and the patient. In an effort to control costs, payers have administrative infrastructure to review
resource utilization by these patients. Additionally payers have developed payment methodologies, usually in
the form of a case rate payment structure, that place facilities and physician providers of HCT at financial risk
for adverse patient financial outcomes in an effort to promote optimal utilization and selection of patients for
HCT. As providers enter into such financial risk arrangements with payers, the providers need to understand
the true cost of care and be able to identify predictable and unpredictable outlier risks for the financial
consequences of medical complications. HCT providers try to protect themselves from excessive financial risk
by having different payment rates for different types of transplant, eg, autologous versus HLA or genotypically
matched related versus HLA mismatched transplants. Because at certain times in the HCT process risk is more
unpredictable, HCT providers require different payment system strategies for the different time periods of
care such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well as short-
and long-term follow-up. Involvement by clinicians is essential for this process to be done well, especially given
the rapid changes technological innovation brings to HCT. Constant dialogue and interaction between
providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this
potentially lifesaving therapy.
© 2004 American Society for Blood and Marrow Transplantation
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sFor the past 20 years, the leading payers of US
ealth care have been attempting to control growth in
ealth-care spending through managed care strate-
ies, either demanding a clinical review and approval
efore services are provided or developing new pay-
ent methods that cause health-care providers to
hare in the ﬁnancial risk of providing care. Health-
are payers in the United States are either employer-
ponsored health plans or government-sponsored
rograms, including Medicare and Medicaid. Em-
loyer-sponsored payers and, to a lesser extent, gov-
rnment-sponsored payers have established managed M
B&MTare organizations (MCOs) to manage utilization of
linical services and the costs of providing medical
are. Managed care is a response to society’s effort to
ontrol the cost of medical services. Providers of ex-
ensive services such as blood and marrow transplan-
ation (BMT) are particularly scrutinized and ﬁnd
heir clinical programs caught up in the whirlwind of
ew methods for pricing medical services and for
nancial accountability.
The ﬁrst efforts to control costs in health-care
ervices involved contracts between providers and
COs for a percentage discount off charges. Because
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4hese arrangements did not fundamentally address the
erception of excessive use of some clinical services
riving up health-care costs, MCOs encouraged pro-
iders to move into capitated compensation methods
n which providers would have the ﬁnancial risk for
roviding clinical services (see Appendix A for a glos-
ary of terms). In a fully capitated plan, providers are
aid a ﬁxed sum to provide all necessary medical care
or a deﬁned population. The logic in capitation is
hat providers with the ﬁnancial risk for providing
dditional clinical services will scrutinize their own
reatment policies to optimize cost-effectiveness. Cap-
tation, whether full or limited, has forced providers
nd MCOs into a mutual effort of trying to identify
nancial risk and setting limits in contracts.
For providers of BMT services, partial risk ar-
angements, often termed case rate contracts, have
een extensively used. These ﬁx reimbursement for
arious components of the transplantation process,
uch as pretransplantation workup, collection of au-
ologous or allogeneic cells, transplantation hospital-
zation, and posttransplantation follow-up care for a
eﬁned period of time. Payers prefer to carve out
MT services with case rate agreements to better
ontrol and predict the costs associated with BMT
ervices. Case rate reimbursement methods share
any features of capitation. Case rates pay a ﬁxed
rice for all clinical services in a deﬁned time period.
roviders are thus at risk for new drugs added to
mprove outcomes or to treat unexpected complica-
ions or comorbidities during this period. To effec-
ively price services, providers must understand these
xed and variable costs during this period and must
nterpret the risk of any individual patient or group of
atients of being an outlier in need of additional ser-
ices. The most costly services cannot be easily ﬁxed
ecause of the unpredictable consequences of BMT,
uch as regimen-related toxicities, infections, and
raft-versus-host disease (GVHD). Because of this,
ost contracts include outlier clauses to cover the
osts of patients with major complications.
BMT providers continue to experience pressure
rom payers to compete for inclusion in Centers of
xcellence networks, which involve both a review of
uality of care delivered and competitive ﬁnancial
erms. The patients covered in these arrangements
ave their choices limited by the contracted network
f transplantation programs. From the provider per-
pective, these contracts involve discounted pricing in
xchange for increased patient volumes. To market
hese networks as quality providers to employer
roups, payers require in-network providers to meet
omprehensive clinical quality standards and to par-
icipate in national reporting of outcomes to an out-
omes reporting registry, such as the International
one Marrow Transplant Registry [1]. Payers gener-
lly require in-network providers to have their cell- M
28rocessing laboratory accredited separately by the
merican Association of Blood Banks [2] or to have
he entire program—including the physicians, the fa-
ility, and the cell-processing laboratory—accredited
s an integrative program by the Foundation for Ac-
reditation of Cellular Therapies. Foundation for Ac-
reditation of Cellular Therapies credentialing as-
esses the integration of a clinical program, the
rogram’s ability to follow its standard operating pro-
edures, and, most importantly, the quality-improve-
ent procedures and policies [3,4]. For a clinical ser-
ice as complex as BMT, the ability of a program to
aintain a continuing quality-improvement program
s vital. This demand by payers for credentialing of
rograms has probably improved the quality of care in
his ﬁeld.
BMT patients may have coverage with 2 or more
nsurance companies. Typically, there is a primary
nsurance company, which may be a self-funded plan
y their employer, and a reinsurance plan for cata-
trophic coverage. Involvement of multiple payers is
omplex, and there is frequently conﬂicting beneﬁt
anguage among the reinsurance, the primary health
nsurance, and the self-funded insurance plans. Most
atients are unaware of these beneﬁt language limita-
ions. The BMT program provider must understand
ow these limitations will affect care before starting
he BMT procedure.
To remain competitive with the market, it is es-
ential for BMT programs to identify and fully under-
tand the true costs of providing patient care. Costs
ary greatly by diagnosis, patient age, comorbidities,
ype of transplantation, histocompatibility, and other
atient- and disease-related factors. The provider
ust be familiar with the types of patients being
reated, the special needs of those patients, and the
isks of major complications, which result in increased
osts.
There are many cost drivers for BMT: the fore-
ost is patient expectations. Patients are aware that a
MT is a once-in-a-lifetime event, and they desire to
ave the transplantation at the best facility featuring
he latest technologic innovations and with the best
ossible outcomes. At the same time, patients want to
ave the transplantation where they can be sur-
ounded by their social support system, including fam-
ly and friends. Hospitals strive to provide the most
ffective, state-of-the-art health care. As with all new
echnology challenges, there are escalating costs for
ncorporating new technologies and drugs.
BMT is typically performed for patients with life-
hreatening diseases and malignancies, often in an
dvanced stage. BMT is frequently a patient’s last
hance for life. BMT involves substantial risks, but it
s typically performed with curative intent. Treatment
tandards are rapidly evolving and poorly deﬁned.
ost transplantations are performed on a clinical re-
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Bearch protocol to address important therapeutic
uestions and so that outcomes can be studied and
eported. Typically, centers study a modiﬁcation of
omponents of the basic transplantation regimen de-
igned to improve the safety and efﬁcacy of the pro-
edure. It is self-evident that continued clinical re-
earch is necessary to improve the standard of care
nvolving BMT. Most insurance plans, however, have
xclusions for investigational and experimental proce-
ures. There is considerable tension between provid-
rs and payers regarding inclusion of patients in clin-
cal research studies. In many cases, carriers will
icromanage the preparative regimen or other treat-
ent administered by the transplant centers, and
ome carriers forbid patients from participating in any
linical trials. These considerations seriously impair
he conduct of clinical research needed to advance the
tandard of care for hematologic malignancies and for
ematopoietic transplantation in general. It is partic-
larly difﬁcult to obtain insurance authorization for
linical trials evaluating hematopoietic transplantation
or novel indications, such as selected solid tumors and
utoimmune diseases, for which this approach seems
romising. In many cases, the payers are sympathetic
o the needs for ongoing clinical research but are
onstrained by the patient’s policy contract language,
hich precludes their participation in any research
tudies.
Selection of candidates for hematopoietic trans-
lantation is another area of tension between trans-
lant centers and the medical insurance industry.
hird-party payers have a ﬁnancial interest to limit
ayments and generally advocate conservative policies
estricting patient selection to favorable risk catego-
ies. Transplantation may still offer an opportunity for
ong-term survival in high-risk patients and those with
dvanced disease. Many clinical trials focus on mea-
ures to improve the outcome in these patients. Often
hese high-risk patients have no alternative options for
ong-term survival other than BMT.
Allogeneic BMT services must account for donor
osts. The donor is having a medical procedure that is
ot for his or her beneﬁt, and, logically, the recipient’s
ealth-care provider—not the donor’s—should be
illed for these costs. Initially, most insurance provid-
rs accepted this responsibility, but donor expenses
re beginning to be denied. Donors frequently have
oexisting medical problems that may not be appreci-
ted before transplant donation. Untreated medical
roblems such as diabetes, hypertension, and cardio-
ascular disease are often identiﬁed. These donors
ay require additional testing to medically clear them
or the transplantation. Additionally, if the donor has
complication as a result of this procedure, the recip-
ent or recipient’s insurance should be obligated to pay
he cost of treatment.Allogeneic BMT generally requires identiﬁcation b
B&MTf a related or unrelated donor who is closely matched
or the human HLA histocompatibility antigens. His-
ocompatibility testing of potential donors is usually
nadequately covered in a capitated model. Many pay-
rs either do not cover histocompatibility typing costs
r have restrictions on the numbers of individuals who
an be tested. In addition to siblings, parents and
hildren should be HLA-typed. If there is no histo-
ompatible donor in the family, an unrelated donor
earch must be performed. It is very difﬁcult to accept
ull typing capitation risk, because families are of dif-
erent sizes and because HLA typing is expensive.
ew molecular-based typing methods appeared
uickly, adding to provider difﬁculty in predicting
ost. Most insurance plans stipulate that the National
arrow Donor Program registry charges be a pass-
hrough without compensating the transplant center
or administrative costs associated with the donor
earch.
The patient’s private insurance carrier must pre-
uthorize nearly all BMT procedures. This process
enerally requires a letter of medical necessity in
hich the transplant center describes the patient’s
haracteristics, diagnosis, age, comorbidities, prior
reatment and response, and current disease status.
etailed patient-speciﬁc correspondence must be pre-
ared and mailed to the insurance provider. Authori-
ation generally takes 2 to 4 weeks and may require
utside review by a panel appointed by the insurance
arrier. This review often delays implementation of
ppropriate therapy, and in many cases an additional
ourse of standard chemotherapy is needed to stabilize
he patient’s disease until insurance authorization is
btained to proceed with the transplantation.
Providers offer different case rates for each dis-
inct type of transplantation. Typically, transplanta-
ion contracts have separate case rates for autologous
ransplantations, HLA-identical sibling transplanta-
ions, HLA-mismatched transplantations, and unre-
ated transplantations. A transplant center must un-
erstand its risk and cost for all types of BMT. To
ssist in billing this complex transplantation proce-
ure, most agreements are divided into phases of ser-
ice—evaluation, pretransplantation care, donor
earch, harvest, transplantation phase (which includes
he preparative regimen, cell infusion, and hospital-
zation until the patient has recovered from neutrope-
ia), short-term follow-up care (1-3 months), and
ong-term follow-up care. Unfortunately, each insur-
nce plan designates these phases differently; this
omplicates the transplant centers’ efforts to develop a
tandardized billing and accounting system. The
MT evaluation usually occurs in the context of can-
er management and in the context of pretransplan-
ation care for the malignancy. The reimbursement by
ayers for costs of general disease management must
e separated from any reimbursement case rate costs
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4ssociated with BMT evaluation and the transplanta-
ion, because costs for management of this disease are
ery unpredictable.
During the pretransplantation process, decisions
ust be made regarding the type of transplant needed—
utologous, syngeneic, or allogeneic. For allogeneic
ransplantations, the donor (related or unrelated) and
ell source (bone marrow, peripheral blood stem cells,
r cord blood) must be determined. Cell harvesting
hould be considered separately from the transplanta-
ion in contracts because of the issue of donor charges
nd, in the case of autologous transplantations, the
ossibility of a “harvest and hold,” in which the donor
ells are harvested while the patient’s disease is in
emission, to be used at a later date.
The next phase is the transplant hospitalization,
uring which the preparative regimen is administered
nd the hematopoietic progenitor cells are infused.
his usually includes the preparative chemotherapy
egimen, the period of cytopenia, and the period lead-
ng up to the immediate time of graft recovery. There
re short-term follow-up issues for autologous trans-
lantations but more so for allogeneic transplanta-
ions, for which the patients cannot go back to a
ommunity hospital after hematopoietic recovery and
ust remain at the transplant facility because of man-
gement of GVHD and viral infection. This phase
sually ends 100 days after cell infusion.
Patients undergoing hematopoietic transplanta-
ion may develop late complications, particularly after
llogeneic transplantation. Long-term follow-up eval-
ation is necessary to monitor patients for disease
ecurrence and for late complications of the proce-
ure, particularly chronic GVHD, infections, and de-
ayed toxicities of chemoradiotherapy. Community
ncologists and other physicians are generally not
amiliar with these late effects and the necessary care
or transplant recipients. Patients are best served by
ollow-up care at their transplant center by profes-
ionals most knowledgeable about the risk and man-
gement of these complications. Many insurance car-
iers do not cover follow-up care by the transplant
enter after the immediate posttransplantation period,
nd this clearly compromises patients’ overall man-
gement. Patients who are having transplant-speciﬁc
anagement problems, such as chronic GVHD or
nfections unique to the transplant population, cannot
e effectively managed in the community. Appropriate
rovisions need to be made for the necessary long-
erm evaluation and care of these patients. Transplant
enters usually are inadequately reimbursed for costs
f care for BMT patients with long-term complica-
ions under a “full service” agreement.
The other issue faced with transplantations is con-
ending with patients who undergo relapse of their
alignancy after allogeneic transplantation. This gen-
rally requires additional chemotherapy treatment c
30nd, often, donor lymphocyte infusion to boost im-
une graft-versus-malignancy effects. There is a high
egree of variability in the cost of this care.
There are also new issues related to advances in
he standards of care in hematopoietic transplantation,
uch as the use of double transplantations for multiple
yeloma, which involve either tandem autologous
ransplantations or an autologous followed by an al-
ogeneic transplantation. The use of nonmyeloablative
llogeneic transplantation has some potential for re-
ucing costs for the initial transplantation, although
he major costs are the management of posttransplan-
ation GVHD and the general costs of care for the
omorbidities in the older and more debilitated pa-
ients who are generally considered for this approach.
BMT is an area of rapid progress and incorporates
ew drugs, biologicals, and technologies. These new
odalities typically are associated with additional cost,
hich is a source of tension with third-party payers.
or example, the addition of rituximab to an autolo-
ous or allogeneic transplantation regimen adds thou-
ands of dollars to charges, generally without any
hange in ﬁxed rate or capitated contracts.
Several high-cost pharmacy items have now come
n to the transplant arena. These include new drugs
or the preparative regimen, such as rituximab, gem-
uzumab ozogamicin, ibritumomab tiuxetan, and
rastuzumab. New drugs are also being used for post-
ransplantation complications, such as recombinant
ctivated factor VII and palivizumab. These drugs
ften have a cost potential equivalent to that of the full
istoric case rate prices previously negotiated. Acqui-
ition costs for the transplant center for some of these
rugs are equivalent to the full case rate prices previ-
usly negotiated.
One important aspect of hematopoietic transplan-
ation contracts is the consideration for outlier risks:
atients with major complications that result in long-
erm hospitalization, intensive care unit care, or both.
atastrophic complications such as graft rejection,
eno-occlusive disease, early acute GVHD, early se-
ere viral infections, or pulmonary hemorrhage may
ccur. Payers and providers should provide terms for
ayment for these cases; this has generally been han-
led as a discount off charges once the total charges
xceed a threshold value. Even in the best-risk pa-
ients, catastrophic complications can occur, and
harges may exceed $1 million. Although it is possible
o identify high-risk groups, such as older patients,
hose with comorbidities, and those with advanced
ematologic malignancies, these patients may still
eneﬁt from a transplantation procedure, which may
e the only lifesaving treatment option available. Re-
ent advances such as reduced-intensity and nonmy-
loablative transplantation have made this form of
reatment feasible for patients who were previously
onsidered ineligible.
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BNew electronic billing systems and Health Insur-
nce Portability and Accountability Act regulations
re forcing payers and providers back in to an ex-
hange of ﬁnancial information that very much resem-
les the old indemnity format. However, payers are
ot willing to pay the previous prices associated with
ndemnity formats. For example, pharmaceutical pay-
rs are demanding to pay the drug-acquisition cost.
or providers, this raises the question of how to best
btain adequate compensation for complex nursing
nd facility services that have not been historically
ell compensated and have used surrogate laboratory
r pharmacy charges for indirect or cost-sheltered
ompensation.
BMT is an area of active clinical research. In many
enters, all patients are treated on clinical research
rotocols designed to address disease- and treatment-
elated problem areas. The standards of care in allo-
eneic and autologous transplantations have markedly
mproved over the last several decades as a result of
linical investigations, and continued support for clin-
cal trials by the medical insurance industry is critical.
nder the Health Insurance Portability and Account-
bility Act, tracking transplantation outcomes without
ntering all patients on efﬁcacy documentation stud-
es, which are essentially phase II studies, has become
ncreasingly difﬁcult. Many payers strongly desire that
nstitutions report transplantation outcomes to them.
he best way to analyze and report outcomes and still
eet regulatory requirements would be to enroll all
atients in clinical research studies.
President Clinton signed an executive memoran-
um on June 7, 2000, that directed the Secretary of
ealth and Human Services to “explicitly authorize
Medicare) payment for routine patient care costs and
osts due to medical complications associated with
articipation in clinical trials” [5]. This was a land-
ark executive order. The executive order was not
verturned by the George W. Bush administration,
ut implementation of the executive order has been
roblematic. The Centers for Medicare and Medicaid
ervices beneﬁts for transplantation include both au-
ologous and allogeneic transplantation for aplastic
nemia and acute and chronic leukemia and autolo-
ous transplantation for Hodgkin disease, lymphoma,
r multiple myeloma [6]. Additionally, there are BMT
eneﬁts for children with genetic disorders of immu-
ity. There is a Center for Medicare and Medicaid
ervices national coverage decision restricting multi-
le myeloma patients to autologous transplantation
nly; a new congressional act will probably be neces-
ary to offer Medicare patients an allogeneic trans-
lantation for this disease. Studying the efﬁcacy of
MT for noncovered areas has been seen as a beneﬁts
overage issue for Centers for Medicare and Medicaid
ervices and not as a clinical trials issue. Thus, the
ollowing is problematic for Medicare beneﬁciaries: p
B&MTllogeneic transplantations are not covered for myelo-
ysplastic syndrome, multiple myeloma, and lym-
homa, settings in which the transplantation can be
urative. Although Medicare generally covers patients
lder than 65 years of age, younger patients who are
edicare beneﬁciaries because of disability from ma-
ignancy are also denied access to services that a rou-
ine commercial insurance would pay as standard of
are for their condition.
In summary, developing contracts with third-party
roviders for BMT is an increasingly challenging pro-
ess. BMT providers must have an integrated con-
racting process with clinical services, ﬁnancial coun-
elors, and billing services. Good communications
mong payers, providers, and human resource ofﬁcers
rom employers are required to successfully meet pa-
ient needs. Payer evaluation and approval for trans-
lantation services need to be accomplished rapidly
or these acutely ill patients. BMT providers must
ealistically price their services to meet society’s
ealth-care funding restraints. Transplantation pro-
iders have historically not entered the policy arena,
ut active engagement is necessary to update and
mprove government payment policies. BMT sits on
he cutting edge of societal health-care ﬁnance issues,
nd its providers must engage MCOs and federal and
tate payers to ensure patient access to this lifesaving
orm of treatment.
PPENDIX A: GLOSSARY OF TERMS
Capitation: Fixed payment arrangements for
embers are made on the basis of the population for
ervices. This is often expressed as payment per mem-
er per month.
Carve-out services: Certain services are carved
ut or not included in the global payment price for
atients for whom there is a global payment for a
ervice.
Fixed and marginal variable costs: In any given
nstitution’s cost structure, there are ﬁxed costs, such
s buildings, beds, and infrastructure. There are mar-
inal variable costs associated with taking care of ad-
itional incremental patients in a speciﬁed infrastruc-
ure. For example, running a night shift of technicians
o perform additional laboratory tests or hiring an extra
ursing shift to manage clinics that overﬂow into the
vening would be included in marginal variable costs.
Fixed risk case rates: A ﬁxed amount of money
or a give type of service.
Outlier risks: There is often speciﬁc language to
over patients who are under a global payment struc-
ure or a capitation system. Frequently the costs for
hese patients become outliers because they are very
ifferent from those of most patients.
Partial risk arrangements: A speciﬁc payment
er service versus a ﬁxed global payment.
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4Reinsurance: Third-party administrators run
ost health insurance organizations, and their pri-
ary function is to process claims for self-insured
ealth plans. Most corporations have a reinsurance
olicy that kicks in to cover health-care beneﬁts for
atastrophic claims, such as when a member’s health-
are expenses exceed $50000 or when the global
ealth-care expenses for that corporation exceed a
ertain cap.
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